OCLG .0033 HUGE DD >> FDA Approved Medical Devices
Post# of 63824
Posted On: 05/30/2015 12:52:40 PM
OCLG .0033 HUGE DD >> FDA Approved Medical Devices + More >>
Oncologix provides FDA approved medical devices, State licensed healthcare services and medical product sales.
The company has a valid registration from FDA as a Class II medical device, and is licensed by Health Canada, a CE mark for Europe. Also Numerous Patents/Trademarks.
Current Share Structure
750,000,000 A/S with 233,071,692 O/S and 101,000,000 Restricted Inside.
FLOAT 133,071,692 As of APRIL 2015
Current Assets $3.6m with almost $5.0m in Revenues BUT it gets better...
Major Acquisition News in Play 2015, year-end objective of $35 million in Top-line revenues with positive EBITDA exceeding $4.0 million.
Growth with 4 Acquisitions >>
We acquired Dotolo Research Corporation (“DOTOLO”) on March 22, 2013, Angels of Mercy, Inc. (“AOM”) on August 1, 2013, Amian Health Services on December 10, 2013, and Esteemcare Inc. on September 25, 2014
Currently Employ 191 Full/Part Time Employees with Operations in Michigan, Louisiana, Arizona
FDA APPROVED CLASS II >>
Oncologix Tech, Inc. is a diversified medical holding company that operates and manufactures Class II medical device products, delivers Personal Healthcare Services and distributes Home Medical and Durable Medical products nationally. For its clients, Oncologix provides FDA approved medical devices and products as well as state licensed healthcare services. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company’s corporate mission is to be the best small cap medical holding company delivering devices, medical products & technologies, and healthcare services in North America.
Current Acquisition Status Update
We continue to pursue our previously announced acquisition target generating $9.8 million in revenues.
We recently added an additional acquisition candidate to our Home Medical/Durable Medical Equipment (DME) division who is located in the same geographic market as our initial target.
These combined acquisition targets will potentially increase OCLG's total annualized revenues by $19.5 million and annualized EBITDA by $3.3 million.
The combined acquisition targets provide an asset base adequate to capitalize the acquisitions and provides numerous operational synergies across our HME/DME platforms.
Post-Acquisition Plans
The reduction of OCLG convertible debt which will reduce significantly shareholder dilution.
Elimination of subsidiary debt which will improve operational cash flows and provides continued, internal organic growth.
OCLG applies to return to the OTC: Bulletin Board.
Evaluate a potential stock repurchase plan to strengthen the stock price and shareholder value.
RECENT NEWS
http://www.otcmarkets.com/stock/OCLG/news
Oncologix provides FDA approved medical devices, State licensed healthcare services and medical product sales.
The company has a valid registration from FDA as a Class II medical device, and is licensed by Health Canada, a CE mark for Europe. Also Numerous Patents/Trademarks.
Current Share Structure
750,000,000 A/S with 233,071,692 O/S and 101,000,000 Restricted Inside.
FLOAT 133,071,692 As of APRIL 2015
Current Assets $3.6m with almost $5.0m in Revenues BUT it gets better...
Major Acquisition News in Play 2015, year-end objective of $35 million in Top-line revenues with positive EBITDA exceeding $4.0 million.
Growth with 4 Acquisitions >>
We acquired Dotolo Research Corporation (“DOTOLO”) on March 22, 2013, Angels of Mercy, Inc. (“AOM”) on August 1, 2013, Amian Health Services on December 10, 2013, and Esteemcare Inc. on September 25, 2014
Currently Employ 191 Full/Part Time Employees with Operations in Michigan, Louisiana, Arizona
FDA APPROVED CLASS II >>
Oncologix Tech, Inc. is a diversified medical holding company that operates and manufactures Class II medical device products, delivers Personal Healthcare Services and distributes Home Medical and Durable Medical products nationally. For its clients, Oncologix provides FDA approved medical devices and products as well as state licensed healthcare services. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company’s corporate mission is to be the best small cap medical holding company delivering devices, medical products & technologies, and healthcare services in North America.
Current Acquisition Status Update
We continue to pursue our previously announced acquisition target generating $9.8 million in revenues.
We recently added an additional acquisition candidate to our Home Medical/Durable Medical Equipment (DME) division who is located in the same geographic market as our initial target.
These combined acquisition targets will potentially increase OCLG's total annualized revenues by $19.5 million and annualized EBITDA by $3.3 million.
The combined acquisition targets provide an asset base adequate to capitalize the acquisitions and provides numerous operational synergies across our HME/DME platforms.
Post-Acquisition Plans
The reduction of OCLG convertible debt which will reduce significantly shareholder dilution.
Elimination of subsidiary debt which will improve operational cash flows and provides continued, internal organic growth.
OCLG applies to return to the OTC: Bulletin Board.
Evaluate a potential stock repurchase plan to strengthen the stock price and shareholder value.
RECENT NEWS
http://www.otcmarkets.com/stock/OCLG/news
(0)
(0)